Composition and method for treating neurological disease
US8895614B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 10, 2014 |
| Grant date | Nov 25, 2014 |
| Priority date | — |
| Expiry date | Jul 10, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/16
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of administering amantadine is provided. The method comprises orally administering to a subject a pharmaceutical composition comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of the amantadine. A dose of the composition provides a mean change in amantadine plasma concentration as a function of time (dC/dT) that is less than 40% of the change in amantadine plasma concentration provided by a dose of the same quantity of an immediate release form of amantadine. The change in plasma concentration over time (dC/dT) is measured in a single dose human pharmacokinetic study in a defined time period of 0 to 4 hours after administration. The amantadine, or pharmaceutically acceptable salt thereof, is administered once daily at a dose of 300 to 500 mg per day.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.